- Home
- VIVS vs BFRI Comparison
VIVS vs BFRI Comparison
Compare VIVS & BFRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VIVS | BFRI |
|---|---|---|
| Founded | 2007 | 1997 |
| Country | United States | United States |
| Employees | N/A | 93 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.1M | 9.7M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | VIVS | BFRI |
|---|---|---|
| Price | $2.40 | $0.84 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $2.75 |
| AVG Volume (30 Days) | 46.0K | ★ 185.7K |
| Earning Date | 11-06-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $140,000.00 | ★ $37,164,000.00 |
| Revenue This Year | $42.38 | $9.70 |
| Revenue Next Year | $15.42 | $10.97 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 35.92 | 5.11 |
| 52 Week Low | $1.41 | $0.54 |
| 52 Week High | $21.96 | $1.87 |
Technical Indicators
Market Signals| Indicator | VIVS | BFRI |
|---|---|---|
| Relative Strength Index (RSI) | 49.83 | 41.35 |
| Support Level | $2.11 | $0.77 |
| Resistance Level | $2.40 | $0.87 |
| Average True Range (ATR) | 0.13 | 0.07 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 54.92 | 52.37 |
Price Performance
Historical ComparisonAbout VIVS VivoSim Labs Inc. Common Stock
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.
About BFRI Biofrontera Inc.
Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy. The Company's licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (together, the RhodoLED Lamps), are used for the treatment of actinic keratoses (AKs), which are pre-cancerous skin lesions.